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Abstract
T-cell protein tyrosine phosphatase (TC-PTP), encoded by Ptpn2, has been shown to function as a tumor suppressor during
skin carcinogenesis. In the current study, we generated a novel epidermal-specific TC-PTP-overexpressing (K5HA.Ptpn2)
mouse model to show that TC-PTP contributes to the attenuation of chemically induced skin carcinogenesis through the
synergistic regulation of STAT1, STAT3, STAT5, and PI3K/AKT signaling. We found overexpression of TC-PTP increased
epidermal sensitivity to DMBA-induced apoptosis and it decreased TPA-mediated hyperproliferation, coinciding with
reduced epidermal thickness. Inhibition of STAT1, STAT3, STAT5, or AKT reversed the effects of TC-PTP overexpression
on epidermal survival and proliferation. Mice overexpressing TC-PTP in the epidermis developed significantly reduced
numbers of tumors during skin carcinogenesis and presented a prolonged latency of tumor initiation. Examination of human
papillomas and squamous cell carcinomas (SCCs) revealed that TC-PTP expression was significantly reduced and TC-PTP
expression was inversely correlated with the increased grade of SCCs. Our findings demonstrate that TC-PTP is a potential
therapeutic target for the prevention of human skin cancer given that it is a major negative regulator of oncogenic signaling.
Introduction
Phosphotyrosine-based signaling plays a significant role in
maintaining cellular homeostasis. The posttranslational
phosphorylation of proteins at tyrosine residues is catalyzed
by protein tyrosine kinases, or PTKs, and the duration of the
phosphorylation state is regulated by protein tyrosine
phosphatases, or PTPs. Mutations that result in aberrant
activation of PTKs can drive cell growth, proliferation, and
survival. Therefore, a great deal of research has focused on
understanding how to target dysregulated PTK signaling for
anticancer therapies [1–3]. Studies utilizing loss-of-function
mouse models further demonstrated that the loss of PTP
signaling is associated with various human diseases like
cancer [4, 5]. However, the effect of PTP overexpression
has not been sufficiently explored due to an initial failure to
establish suitable PTP-overexpressing cell lines and models,
especially in carcinogenesis [4, 6].
T-cell protein tyrosine phosphatase (TC-PTP) is an
intracellular, nonreceptor PTP encoded by the PTPN2 gene
[7, 8]. Alternative splicing at the 3′ end of PTPN2 generates
two distinct isoforms of TC-PTP: TC45 (45 kDa) and TC48
(48 kDa). TC45 is primarily found in the nucleus of most
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cell types, and shuttles between the nucleus and cytoplasm
in response to growth factor and cytokine receptor signaling
[9–11]. In keratinocytes, TC45 can be found in the cyto-
plasm, and it is shuttled to the nucleus by an AKT/14-3-3σ-
mediated mechanism upon TC45 activation [12]. TC-PTP is
involved in various cellular processes including cell pro-
liferation, differentiation, and apoptosis through the nega-
tive regulation of its substrates, like JAK (Janus kinase) 1,
JAK3, STAT (signal transducer and activator of transcrip-
tion) 1, and STAT3 [13–15]. Current research has shown
that deletion or decreased expression of PTPN2 occurs in
human T-cell acute lymphoblastic leukemia, breast cancer
and liver cancer [16–19]. Our studies demonstrated that TC-
PTP functions in vitro and in vivo as a tumor suppressor in
both UV-induced and chemically induced skin cancer due
to its ability to directly suppress STAT3 and Flk-1/
VEGFR2 signaling [20, 21]. Together, these findings sug-
gest that the activation of TC-PTP would be an effective
strategy against different types of cancer. However, an
interesting recent study revealed that the deletion of PTPN2
in tumor cells increased their sensitivity to cancer immu-
notherapy [22]. Obviously, more research is needed to
Fig. 1 Generation of epidermal-specific K5HA.Ptpn2 transgenic
mouse. a Schematic diagram of the construct used to generate HA-
tagged TC-PTP (Ptpn2) transgenic mice using the BK5 promoter.
b Genomic PCR analysis of the transgene using genomic DNA
obtained from the mouse tail. PCR was performed by using the two
primers described in “Materials and methods” to identify the trans-
genic founders. c Western blot analysis of HA, TC-PTP, p-STAT3,
and STAT3 in the epidermis from nontransgenic wild-type (WT) and
K5HA.Ptpn2 mice. Epidermis was collected and total cell lysates from
both genotypes were resolved by SDS-PAGE and immunoblotted with
antibodies specific for HA, TC-PTP, p-STAT3, and STAT3.
d Representative hematoxylin & eosin (H&E) staining and immuno-
histochemical staining of HA-tagged TC-PTP using HA antibody in
the epidermis from both genotypes. Scale bar: 50 μm. e Western blot
analysis of HA in nonepidermal tissues from wild-type and K5HA.
Ptpn2 mice. Brain, heart, liver, lung, and stomach were collected from
both genotypes and total cell lysates were prepared.
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understand the full impact of PTP inhibition or activation on
oncogenesis and the potential use of either in any anticancer
strategies.
In the present study, we generated a new transgenic
mouse model that overexpresses TC-PTP specifically in the
epidermis (K5HA.Ptpn2) to further investigate the role of
TC-PTP in chemically induced skin carcinogenesis. TC-
Overexpression of TC-PTP in murine epidermis attenuates skin tumor formation
PTP overexpression significantly increased DMBA (7,12-
dimethylbenz[a]anthracene)-induced epidermal apoptosis
and reduced TPA (12-O-tetradecanoylphorbol-13-acetate)-
mediated epidermal hyperplasia and hyperproliferation
through the regulation of STAT1, STAT3, STAT5, and
PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase)/
AKT signaling. Furthermore, K5HA.Ptpn2 mice exposed to
a DMBA/TPA regimen clearly exhibited delayed tumor
development and significantly reduced tumor numbers
compared with control mice. We also found TC-PTP
expression was significantly lower in human papillomas and
squamous cell carcinomas (SCCs) in comparison with
normal skin tissue. Our findings provide additional evidence
of the importance of TC-PTP in keratinocyte survival and
proliferation and how its roles in these cellular mechanisms
allow it to function as a major tumor suppressor in skin
cancer.
Results
Generation of transgenic mice overexpressing
TC-PTP in epidermis
In our previous study, we showed that TC-PTP suppresses
keratinocyte survival and proliferation in response to UVB
exposure by directly dephosphorylating activated STAT3
[23]. Using a novel epidermal-specific TC-PTP knockout
mouse model, we also demonstrated that TC-PTP has a
critical role in attenuating chemically induced skin cancer
formation by regulating STAT3 and AKT phosphorylation
[20]. To further investigate the functional role of TC-PTP in
skin carcinogenesis, we generated transgenic mice that
specifically overexpress TC-PTP in epidermis. HA-tagged
mouse Ptpn2 cDNA encoding TC-PTP [23] was amplified
by PCR and cloned into the keratin 5 (K5) expression
vector containing rabbit β-globin intron and simian virus 40
polyadenylation signals to direct cDNA expression (Fig.
1a). The resulting transgene vector was injected into the
pronuclei of donor embryos from FVB/N mice to generate
TC-PTP-overexpressing mice under control of the K5 pro-
moter (K5HA.Ptpn2). The FVB/N strain is highly sensitive
to chemically induced skin carcinogenesis in comparison
with other strains, such as C57BL/N [24], and this strain
also was used to generate our Ptpn2 knockout mouse
model. The transgenic mice were identified by PCR of the
genomic DNA using primers specific for the rabbit β-globin
intron. Three founders—identified as #2, #6, and #11—
were shown to carry the transgene by PCR analysis (Fig.
1b). Western blot analysis of epidermal lysates showed that
of the three founders, #2 and #11 expressed exogenous TC-
PTP as detected by anti-HA antibody and anti-TC-PTP
antibody (Fig. 1c). In correlation with the overexpression of
TC-PTP in epidermis, these two founders also exhibited
decreased expression levels of phosphorylated STAT3 in
comparison with nontransgenic (wild type (WT)) littermates
(Fig. 1c). Immunohistochemical analysis confirmed that
TC-PTP transgenic mice expressed exogenous TC-PTP in
the epidermis, whereas control WT mice did not (Fig. 1d).
In addition, we analyzed protein lysates from other tissues
harvested from TC-PTP transgenic mice and WT control
and verified that exogenous TC-PTP was not expressed in
these other tissues (Fig. 1e). Neither founder displayed any
apparent physical differences from WT mice during
maturation. Similarly, primary keratinocytes derived from
both founders showed similar growth and morphological
characteristics (data not shown). Since the two founders
exhibited similar molecular characteristics, growth patterns,
and morphology, we utilized founder #11 for colony
expansion and subsequent experiments.
Overexpression of TC-PTP increases susceptibility to
DMBA-induced apoptosis
The tumor initiator DMBA causes DNA damage that can
contribute to tumorigenesis if left unchecked; however,
induction of the cell’s natural apoptotic response can
remove aberrant, damaged cells, and prevents their pro-
liferation [25, 26]. To investigate the effect of TC-PTP
overexpression on apoptosis induced by DMBA, primary
keratinocytes derived from either WT or K5HA.Ptpn2 mice
were cultured and treated with DMBA. There were no
visible differences in morphology between control and TC-
PTP-overexpressing keratinocytes before DMBA treatment
(Fig. 2a). However, morphological changes characteristic of
Fig. 2 Effect of TC-PTP overexpression on DMBA-induced
apoptosis in epidermis. a–d Apoptotic response of primary kerati-
nocytes obtained from the epidermis of wild-type and K5HA.Ptpn2
mice after 24 h of DMBA treatment. a Primary keratinocytes from
both genotypes were cultured and treated with 50 nM of DMBA. Scale
bar: 100 μm. b Quantitative analysis of percentage of apoptotic cells
characterized by cell ballooning, nuclear condensation, and bleb for-
mation. After 24 h of DMBA treatment, apoptotic keratinocytes were
counted microscopically in at least three nonoverlapping feilds. The
results are the mean ± s.d.m. from three independent experiments. **P
< 0.01 by Mann–Whitney U test. c Quantification of apoptotic cells in
primary keratinocytes from both genotypes 24 h after DMBA treat-
ment. Apoptotic cells were stained with Annexin V-FITC and ana-
lyzed by using flow cytometry. d Representative crystal violet staining
of primary keratinocytes from wild-type, K5HA.Ptpn2, K14Cre.
Ptpn2fl/fl mice following 24 h of DMBA treatment. e, f Apoptotic
response of the epidermis from both genotypes. Groups of mice (n=
3) were received a single topical application of DMBA (200 nmol) and
sacrificed 24 h later. Skin sections were collected and apoptotic cells
were quantified by immunostaining with caspase-3. e Representative
staining of caspase-3 in the epidermis from both genotypes following
treatment with DMBA. Scale bar: 100 μm. f Quantitative analysis of
caspase-3-positive cells per centimeter of epidermis in both genotypes
after DMBA treatment. **P < 0.01 by Mann–Whitney U test.
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apoptosis, such as cell ballooning and bleb formation, were
significantly increased in TC-PTP-overexpressing kerati-
nocytes compared with control keratinocytes after DMBA
treatment (Fig. 2a, b). Analysis of apoptosis utilizing flow
cytometry demonstrated a clear increase of apoptotic cells
in TC-PTP-overexpressing keratinocytes after DMBA
treatment compared with control (Fig. 2c). We also com-
pared primary keratinocytes derived from our TC-PTP-
deficient mice [20] to control and TC-PTP-overexpressing
keratinocytes after DMBA treatment. While the number of
viable control or TC-PTP-overexpressing keratinocytes was
decreased after treatment in comparison with untreated
keratinocytes, the number of viable TC-PTP-deficient ker-
atinocytes was not (Fig. 2d). Consistent with in vitro results,
the number of apoptotic cells within the epidermis of K5HA.
Ptpn2 transgenic mice, which was detected by active
caspase-3 staining, was significantly increased compared
with control mice epidermis 24 h after DMBA treatment
(Fig. 2e, f). These results support our hypothesis that TC-
PTP plays a tumor suppressive role in epidermis by facil-
itating the removal of tumor-initiating keratinocytes upon
DMBA exposure.
TC-PTP overexpression increases DMBA-induced
apoptosis through the synergistic regulation of
STAT1, STAT3, STAT5, and AKT signaling pathways
We have shown that TC-PTP dephosphorylates STAT3 in
both mouse and human keratinocytes [23, 27]. We also
have demonstrated that the loss of TC-PTP promotes che-
mically induced skin carcinogenesis through the activation
of STAT3 and AKT signaling. To further investigate the
role of TC-PTP in the regulation of these signaling path-
ways during DMBA-induced tumor initiation, primary
keratinocytes derived from either WT or K5HA.Ptpn2 mice
were treated with different concentrations of DMBA for 1 h
and then cultured in serum-free medium for 1 h in order to
observe the initial response to DMBA. DMBA treatment
increased the expression levels of tyrosine-phosphorylated
STAT3 (pY-STAT3) in control keratinocytes compared
with TC-PTP-overexpressing keratinocytes; whereas serine-
phosphorylated STAT3 (pS-STAT3) was constitutively
expressed in both genotypes in the presence or absence of
DMBA (Fig. 3a). In our previous studies, we demonstrated
Fig. 3 TC-PTP overexpression
sensitizes DMBA-induced
apoptosis through regulation
of STAT and AKT signaling
pathways. a, b Primary
keratinocytes from wild-type
and K5HA.Ptpn2 mice were
cultured and treated with DMBA
(50, 100, and 200 nM).
Following the 1 h pulse
treatment of DMBA, cells were
cultured for 1 h and total cell
lysates were prepared. aWestern
blot analysis of p-STAT1, p-
STAT3, and p-STAT5 in
primary keratinocytes from both
genotypes after DMBA
treatment. b Western blot
analysis of p-PI3K and p-AKT
in primary keratinocytes from
both genotypes after DMBA
treatment. c Primary
keratinocytes from wild-type
and K5HA.Ptpn2 mice were
cultured and treated with DMBA
(100 nM). Western blot analysis
of p-STAT1, p-STAT3, p-
STAT5, p-AKT, and Bax in
primary keratinocytes from both
genotypes after DMBA
treatment.
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that, unlike STAT3, neither STAT1 nor STAT5 were
initially dephosphorylated by PTP in keratinocytes follow-
ing UVB irradiation [27]. Similarly, DMBA did not induce
either STAT1 or STAT5 activation in either genotype
during the 1 h culture period following treatment (Fig. 3a).
In addition, we examined the effects of TC-PTP over-
expression on PI3K/AKT signaling during the cellular
response to DMBA, and we found phosphorylation of
PI3K, the upstream regulator of AKT, was completely
blocked by DMBA treatment in both genotypes. The
expression levels of phosphorylated AKT in control kera-
tinocytes were higher in comparison with TC-PTP-
overexpressing keratinocytes after DMBA treatment (Fig.
3b).
Fig. 4 Inhibition of STAT1, STAT3, STAT5, or AKT on DMBA-
induced apoptosis in keratinocytes. a Representative photo-
micrographs of primary keratinocytes from wild-type and K5HA.Ptpn2
mice. Primary keratinocytes from both genotypes were pretreated with
STAT3 inhibitor STA21 (10 μM), STAT5 inhibitor N′-((4-Oxo-4h-
chromen-3-yl)methylene)nicotinohydrazide (5 μM), AKT inhibitor
A6730 (1 μM), or STAT1 inhibitor Fludarabine (10 μM) for 1 h before
DMBA treatment (100 nM). Following the 1 h pulse treatment of
DMBA, cells were cultured for 24 h. Scale bar: 100 μm. b Effect of
inhibition of STAT3 or STAT5 on DMBA-induced apoptosis. Primary
keratinocytes from both genotypes were pretreated with STAT3
inhibitor or STAT5 inhibitor for 1 h before DMBA treatment.
Following the 1 h pulse treatment of DMBA, cell viability was mea-
sured after 24 h of DMBA treatment using WST-assay. *P < 0.05 by
ANOVA. c Effect of inhibition of AKT on DMBA-induced apoptosis.
Primary keratinocytes from both genotypes were pretreated with AKT
inhibitor for 1 h before DMBA treatment. Following the 1 h pulse
treatment of DMBA, cell viability was measured after 24 h of DMBA
treatment using WST-assay. **P < 0.01 by ANOVA. d Effect of
inhibition of STAT1 on DMBA-induced apoptosis. Primary kerati-
nocytes from both genotypes were pretreated with STAT1 inhibitor for
1 h before DMBA treatment. Following the 1 h pulse treatment of
DMBA, cell viability was measured after 24 h of DMBA treatment
using WST-assay. *P < 0.05 by ANOVA.
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Next, primary keratinocytes derived from both genotypes
were treated with DMBA for 1 h and then cultured over a
24 h period to evaluate the effect of TC-PTP overexpression
on the long-term response to DMBA. Western blot analysis
showed that DMBA treatment induced an increase in the
expression levels of pY-STAT3 and phosphorylated AKT
in control keratinocytes when compared with TC-PTP-
overexpressing keratinocytes. We also observed that the
levels of pY-STAT5 were increased in control keratinocytes
when compared with TC-PTP-overexpressing keratinocytes
during the long-term (24 h) culture period following DMBA
treatment (Fig. 3c). Furthermore, while the expression
levels of pY-STAT1 and total STAT1 were higher in con-
trol keratinocytes in comparison with K5HA.Ptpn2 kerati-
nocytes following DMBA treatment, the levels of pS-
STAT1 were increased in K5HA.Ptpn2 keratinocytes
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compared with control (Fig. 3c). The expression levels of
Bax and cleaved caspase-3 also were higher in K5HA.Ptpn2
keratinocytes (Fig. 3c), suggesting serine phosphorylation
of STAT1 corresponds to increased DMBA-induced
apoptosis.
Inhibition of STAT3, STAT5, or AKT with a specific
inhibitor before DMBA treatment significantly reduced cell
viability in WT cells in comparison with DMBA-only
control cells (Fig. 4a–c). On the other hand, STAT1 inhi-
bition significantly increased cell viability in TC-PTP-
overexpressing keratinocytes in comparison with DMBA-
only control cells (Fig. 4a, d), indicating that tyrosine
phosphorylation of STAT1 does not play a role in the cell
viability of keratinocytes during tumor initiation. Our
findings suggest that TC-PTP protects keratinocytes during
tumor initiation by promoting DMBA-induced apoptosis
via the positive regulation of STAT1 serine phosphorylation
and the negative regulation of STAT3, STAT5, and AKT
signaling.
TC-PTP overexpression suppresses TPA-induced
epidermal hyperproliferation and hyperplasia
DNA-damaged cells that escape apoptosis during tumor
initiation possess a growth advantage that drives prolifera-
tion, resulting in epidermal hyperplasia during tumor pro-
motion [26]. To examine whether TC-PTP overexpression
can reduce TPA-induced keratinocyte hyperproliferation
and epidermal hyperplasia, primary keratinocytes derived
from WT and K5HA.Ptpn2 mice were cultured. TC-PTP-
overexpressing keratinocytes grew significantly slower than
control keratinocytes after 48 and 72 h of culture (Fig. 5a).
Keratinocytes from both genotypes showed an initial
decrease in growth rate after TPA treatment for 1 h. Fol-
lowing the short lag period, both cell lines began to grow
again. However, TC-PTP-overexpressing keratinocytes
proliferated significantly slower than WT (Fig. 5b, c).
To examine whether or not overexpression of TC-PTP
has an inhibitory effect on TPA-induced hyperproliferation
and hyperplasia in vivo, both control and TC-PTP trans-
genic mice were treated with TPA over a 72 h period. As
shown in Fig. 5d, e, there were no significant differences in
the epidermal thickness between the two genotypes in the
absence of treatment. However, topical application of TPA
significantly increased epidermal thickness of WT mice in
comparison with K5HA.Ptpn2 transgenic mice 24, 48, and
72 h after treatment (Fig. 5d, e). Analysis of epidermal cell
proliferation using BrdU labeling and PCNA staining also
showed the similar results. Following TPA treatment, the
number of either BrdU-positive or PCNA-positive cells in
the epidermis of WT mice was significantly increased
compared with K5HA.Ptpn2 transgenic mice (Fig. 5f–i).
These findings further demonstrate that TC-PTP can protect
skin against TPA-induced epidermal hyperproliferation and
hyperplasia.
TC-PTP overexpression reduces TPA-induced
proliferation through the synergistic regulation of
STAT1, STAT3, STAT5, and PI3K/AKT signaling
pathways
To investigate the regulatory role of TC-PTP during tumor
promotion, primary keratinocytes from both WT and K5HA.
Ptpn2 mice were treated with TPA for 1 h and then cultured
over a 4 h period in order to observe the initial response to
TPA. As shown in Fig. 6a, TPA treatment induced a sig-
nificant increase of pY-STAT3, pY-STAT1, and pY-
STAT5 expression levels over time in control keratino-
cytes in comparison with TC-PTP-overexpressing kerati-
nocytes. In contrast, TC-PTP-overexpressing keratinocytes
showed a significant increase of pS-STAT1 in response to
TPA treatment (Fig. 6a). Overexpression of TC-PTP also
inhibited phosphorylation of PI3K in the presence and
absence of TPA. Consistently, the levels of phosphorylated
AKT in control were higher when compared with TC-PTP-
overexpressing keratinocytes with or without TPA treat-
ment (Fig. 6b).
Next, primary keratinocytes from both genotypes were
treated with TPA for 1 h and then cultured over a 72 h
period to check the long-term effect of TC-PTP over-
expression on the response to TPA treatment. Western blot
analysis revealed a decrease of pY-STAT3 over time in
both genotypes; but, levels of pY-STAT3 in TC-PTP-
overexpressing keratinocytes were, again, clearly reduced in
comparison with WT (Fig. 6c). There was no visible
expression of pY-STAT1 or pY-STAT5 in either
Fig. 5 Effect of TC-PTP overexpression on epidermal hyperpro-
liferation induced by TPA. a Equivalent number of primary kerati-
nocytes from wild-type and K5HA.Ptpn2 mice were seeded and
cultured for 72 h. Proliferation of primary keratinocytes was measured
by using the WST-assay. *P < 0.05 by Mann–Whitney U test. The
results are the mean ± s.d.m. b Primary keratinocytes were treated with
TPA (50 nM) for 1 h. Proliferation of primary keratinocytes was
measured using WST-assay. *P < 0.05 by Mann–Whitney U test. The
results are the mean ± s.d.m. c Representative photomicrographs of
primary keratinocytes from both genotypes at 24, 48, and 72 h after
50 nM of TPA treatment for 1 h. Scale bar: 100 μm. d–i Groups of
mice (n= 3/group) were treated topically with single application of
TPA (6.8 nmol) and sacrificed 24, 48, and 72 h after treatment. d
Representative H&E staining of epidermis from both genotypes of
mice. Scale bar: 50 μm. e Quantification of epidermal thickness from
both genotypes treated with TPA. **P < 0.01 by Mann–Whitney U
test. f Representative BrdU staining of epidermis from both genotypes
of mice. Scale bar: 100 μm. g Quantification of BrdU-labeled kerati-
nocytes from epidermis of both genotypes. **P < 0.01 by
Mann–Whitney U test. h Representative PCNA staining of epidermis
from both genotypes of mice. Scale bar: 100 μm. i Quantification of
PCNA-positive keratinocytes from epidermis of both genotypes. **P
< 0.01 by Mann–Whitney U test.
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keratinocyte genotype. However, the results revealed an
increase of pS-STAT1 24 h after TPA treatment in both
genotypes, with K5HA.Ptpn2 keratinocytes expressing
higher levels of pS-STAT1 than WT keratinocytes even
though the level of total STAT1 was lower in TC-PTP-
overexpressing cells than control cells (Fig. 6c). Like
STAT3, TPA treatment reduced phosphorylation of PI3K
over time; however, levels of phosphorylated PI3K were
much lower in TC-PTP-overexpressing keratinocytes than
control keratinocytes (Fig. 6c). Consequently, the level of
phosphorylated AKT was lower in TC-PTP-overexpressing
cells than control cells following TPA exposure. To
examine the potential effects of STAT- and PI3K/AKT-
mediated signaling on cell proliferation and apoptosis, we
analyzed the expression levels of different well-known
markers. Expression of cyclin D1 appeared to be higher in
WT keratinocytes compared with TC-PTP-overexpressing
keratinocytes (Fig. 6c). The levels of the antiapoptotic
proteins Bcl-2 and Bcl-xL were also higher in WT cells than
TC-PTP-overexpressing cells and they showed a time-
dependent increase. In contrast, expression levels of Bax
increased in a time-dependent manner only in K5HA.Ptpn2
keratinocytes (Fig. 6c).
Inhibition of either STAT3 or STAT5 with a specific
inhibitor prior to TPA treatment significantly reduced cell
viability in WT cells compared with TC-PTP-
overexpressing cells (Fig. 7a, b). However, inhibition of
both STAT3 and STAT5 did not further reduce cell viability
in WT (Fig. 7b), suggesting STAT3 and STAT5 regulate
the same or similar downstream targets/signaling pathways
during TPA-induced keratinocyte proliferation. Previous
studies showed that TPA induced STAT1 tyrosine phos-
phorylation in mouse epidermis; yet, STAT1 did not have
an effect on TPA-induced skin tumor promotion and for-
mation [28]. We found inhibition of STAT1 prior to TPA
treatment did not reduce cell viability in WT keratinocytes.
In contrast, STAT1 inhibition significantly increased cell
viability in TC-PTP-overexpressing keratinocytes, implying
that TC-PTP-mediated serine phosphorylation of STAT1
inhibits TPA-induced cell proliferation (Fig. 7c). Analysis
of the cell cycle by flow cytometry confirmed that TC-PTP-
overexpressing cells treated with STAT1 inhibitor before
TPA exposure showed cell cycle progression as evidenced
Fig. 6 Overexpression of
TC-PTP in epidermis reduces
TPA-induced cell proliferation
and survival through the
regulation of STAT1, STAT3,
STAT5, and PI3K/AKT
signaling. a–c Primary
keratinocytes from wild-type
and K5HA.Ptpn2 mice were
cultured and collected at the
indicated time after TPA
treatment (50 nM) and total cell
lysates were prepared. aWestern
blot analysis of p-STAT1, p-
STAT3, and p-STAT5 in
primary keratinocytes from both
genotypes after TPA treatment.
b Western blot analysis of p-
PI3K and p-AKT in primary
keratinocytes from both
genotypes. c Western blot
analysis of p-STAT1, p-STAT3,
p-STAT5, p-PI3K, p-AKT,
cyclin D1, Bcl-2, Bcl-xL, and
Bax in primary keratinocytes
from both genotypes after TPA
treatment.
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by an increase of cells in the S phase and the G2/M phase of
the cell cycle (Fig. 7d; Supplementary Fig. S1). Similar
results were observed for PI3K/AKT signaling. Inhibition
of either PI3K or AKT prior to addition of TPA sig-
nificantly reduced cell viability in control keratinocytes;
however, their inhibition had no effect on cell viability of
TC-PTP-overexpressing keratinocytes (Fig. 7e, f). These
findings suggest that TC-PTP protects keratinocytes during
tumor promotion by inhibiting TPA-induced cell prolifera-
tion via the negative regulation of STAT3, STAT5, and
PI3K/AKT signaling, and the positive regulation of
STAT1 signaling.
Overexpression of TC-PTP reduces prevalence
of skin tumors stimulated by DMBA/TPA regimen
in mouse
To examine the role of TC-PTP in TPA-induced hyper-
proliferation and hyperplasia in vivo, both control and TC-
PTP transgenic mice were treated with TPA twice weekly
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for 2 weeks. As shown in Fig. 8a, b, repeated application of
TPA to the epidermis significantly increased epidermal
thickness of WT mice in comparison with K5HA.Ptpn2
transgenic mice 24 and 48 h after last treatment. Then, TC-
PTP transgenic and WT mice were subjected to a two-stage
chemical carcinogenesis regimen. Both groups of mice were
treated with DMBA. Two weeks after tumor initiation with
DMBA, mice were treated with TPA twice weekly to pro-
mote tumor formation. Mice overexpressing TC-PTP in
skin were less susceptible to chemically induced skin car-
cinogenesis in comparison with control (Fig. 8c–e). WT
mice started to develop papilllomas 8 weeks after promo-
tion, whereas transgenic mice did not develop papillomas
until 10 weeks after promotion (Fig. 8d). By 15 weeks,
100% of the control group had developed papillomas while
only ~80% of the transgenic group had developed papillo-
mas (Fig. 8d). This difference was statistically significant
after 8 weeks and for the remainder of the experiment (P <
0.05, likelihood-ratio test). The average number of papil-
lomas per mouse was greater in WT compared with K5HA.
Ptpn2 mice (Fig. 8e). There was a significant reduction in
the average number of papillomas per mouse in K5HA.
Ptpn2 transgenic mice compared with WT mice after
10 weeks and for the remainder of the experiment (P < 0.05
by Mann–Whitney U test, Fig. 8e). Immunohistochemical
analysis confirmed that papillomas from K5HA.Ptpn2 mice
expressed both exogenous HA-tagged TC-PTP and endo-
genous TC-PTP, whereas papillomas from WT mice did not
(Fig. 8f). Furthermore, papillomas from TC-PTP-
overexpressing mice showed a clear decrease in levels of
phosphorylated STAT3 and phosphorylated AKT expres-
sion in comparison with control (Fig. 8f).
TC-PTP expression is reduced in human skin tumors
We also analyzed the expression of TC-PTP in human skin
tumors in order to demonstrate the potential significance of
our findings in mice. Immunohistochemical analysis
showed that TC-PTP was expressed in normal human skin
sections (n= 13), but its expression was significantly
decreased in both papillomas (n= 6) and SCCs (n= 57)
(Fig. 9a, b). TC-PTP expression was further decreased with
increased grade of human SCCs (Fig. 9c, d). Immunohis-
tochemical staining of phosphorylated STAT3 (p-STAT3)
and phosphorylated AKT (p-AKT) revealed that their
expression levels were higher in papillomas and SCCs
compared with normal skin sections (Fig. 9e), Quantifica-
tion of staining revealed that the expression of p-STAT3
was significantly (P < 0.0001) inversely correlated with TC-
PTP expression, and p-AKT expression appeared to
decrease (P= 0.044) with increased TC-PTP expression.
(Fig. 9f, g). These findings imply that the loss of TC-PTP-
mediated regulation of STAT3 and AKT signaling may play
an important role in human skin tumor progression.
Discussion
Many studies have demonstrated that PTPs are involved in
the regulation of carcinogenesis, either as tumor suppressors
or tumor promoters. Our early studies showed that PTPs are
initially activated in response to UVB irradiation to protect
keratinocytes from DNA damage-induced transformation
through the negative regulation of STAT3 survival signal-
ing [27]. Further investigation revealed that TC-PTP is the
key PTP involved in the regulation of STAT3 signaling in
keratinocytes following UVB exposure [23]. Recent studies
using an epidermal-specific TC-PTP knockout mouse
model demonstrated that TC-PTP deficiency promotes
resistance to apoptosis and hyperproliferation in the epi-
dermis by regulating both STAT3 and AKT signaling
pathways. Moreover, TC-PTP deficiency in epidermis sig-
nificantly accelerated skin tumor formation in mouse during
skin carcinogenesis induced by DMBA/TPA [20]. In the
current study, we further demonstrate that TC-PTP is a
critical tumor suppressor in skin cancer development by
generating and characterizing an epidermal-specific TC-
PTP-overexpressing mouse model.
Previous studies showed that three STATs—STAT1,
STAT3, and STAT5—are activated in the epidermis after
Fig. 7 Inhibition of STAT1, STAT3, STAT5, PI3K, or AKT dur-
ing TPA-induced keratinocyte survival and proliferation. Primary
keratinocytes from wild-type and K5HA.Ptpn2 mice were pretreated
with STAT1 inhibitor Fludarabine (10 μM), STAT3 inhibitor STA21
(10 μM), STAT5 inhibitor N′-((4-Oxo-4h-chromen-3-yl)methylene)
nicotinohydrazide (10 μM), PI3K inhibitor LY294002 (10–20 μM),
and AKT inhibitor A6730 (1–5 μM) for 1 h before TPA treatment. The
results are the mean ± s.d.m. a Representative morphological changes
of primary keratinocytes from both genotypes following treatment of
TPA for 24 h. Scale bar: 100 μm. b Quantitative analysis of percentage
of viable cells after 24 h of TPA treatment. Primary keratinocytes from
both genotypes were pretreated with STAT3 inhibitor and/or STAT5
inhibitor for 1 h before TPA treatment. Following the 1 h pulse treat-
ment of TPA, cell proliferation was measured after 24 h of TPA
treatment using WST-assay. *P < 0.05 by ANOVA. c Quantitative
analysis of cell viability after 24 h of TPA treatment. Primary kerati-
nocytes from both genotypes were pretreated with STAT1 inhibitor for
1 h before TPA treatment. Following the 1 h pulse treatment of TPA,
cell proliferation was measured after 24 h of TPA treatment using
WST-assay. *P < 0.05 by ANOVA. d Cell cycle analysis after 24 h of
TPA treatment. Primary keratinocytes from K5HA.Ptpn2 mice were
pretreated with STAT1 inhibitor for 1 h before TPA treatment. Cell
cycle analysis was performed by flow cytometry after 24 h of TPA
treatment. Effect of inhibition of PI3K or AKT on TPA-induced cell
proliferation in keratinocytes. Primary keratinocytes from both geno-
types were pretreated with either (e) PI3K inhibitor LY294002 or (f)
AKT inhibitor A6730 for 1 h before TPA treatment. Following the 1 h
pulse treatment of TPA, cell proliferation was measured after 24 h of
TPA treatment using WST-assay. *P < 0.05 by ANOVA.
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TPA treatment [29]. We found all three STATs were
phosphorylated at a tyrosine residue in WT primary kera-
tinocytes after either DMBA or TPA treatment, but, TC-
PTP overexpression blocked tyrosine phosphorylation
(Figs. 3c and 6a). Our previous studies showed that TPA
treatment initially reduced the level of pY-STAT3 in control
keratinocytes compared with TC-PTP-deficient keratino-
cytes [20]. The current results demonstrated that the level of
pY-STAT3 expression quickly recovered (at 1 h) post TPA
treatment and gradually increased with time, however,
overexpression of TC-PTP completely inhibited STAT3
phosphorylation (Fig. 6a). In addition, we had previously
found that while the expression levels of pY-STAT3 were
initially decreased in keratinocytes after UVB exposure, the
levels of pY-STAT1 and pY-STAT5 remained changed
[27]. On the other hand, our current results indicated that
DMBA or TPA can induce tyrosine phosphorylation of the
three STATs, and their tyrosine phosphorylation was
negatively regulated by TC-PTP. Interestingly, whereas WT
primary keratinocytes expressed higher levels of pY-
STAT1 than TC-PTP-overexpressing primary keratino-
cytes, the levels of pS-STAT1 were increased in TC-PTP-
overexpressing keratinocytes compared with control kera-
tinocytes after either DMBA or TPA treatment (Figs. 3c and
Fig. 8 TC-PTP overexpression
reduces tumor formation in
the epidermis during two-
stage skin carcinogenesis. a
Representative H&E staining of
epidermis from wild-type and
K5HA.Ptpn2 mice. Both
genotypes of mice were treated
with twice-weekly application of
6.8 nmol of TPA for 2 weeks.
Scale bar: 100 μm. b
Quantification of epidermal
thickness from both genotypes
treated with TPA. **P < 0.05 by
Mann–Whitney U test. c–e
Groups of from wild-type and
K5HA.Ptpn2 mice (n= 13/
group) were treated with
25 nmol DMBA and after
2 weeks treated with twice-
weekly application of 6.8 nmol
of TPA for the duration of the
experiment. c Representative
photograph of both genotypes of
mice at the 21st week of tumor
promotion. d Percentage of mice
with tumors. *P < 0.05 by
likelihood-ratio test. e Average
number of tumors per mouse.
(mean ± s.e.m.). *P < 0.05 by
Mann–Whitney U test. f
Representative
immunohistochemical staining
of p-STAT3, p-AKT, HA, and
TC-PTP in papillomas from both
genotypes. Scale bar: 20 µm.
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Fig. 9 TC-PTP expression in human skin tumors. a Representative
immunohistochemical staining of TC-PTP in normal human skins (n
= 13), papillomas (n= 6), and squamous cell carcinomas (SCCs) (n=
57). Scale bar: 5 µm. b Quantification of TC-PTP expression by
immunohistochemistry (IHC) scoring. Percentage of cells showing
more than IHC score 5. TC-PTP expression levels from each of section
were assessed as described in “Materials and Methods.” **P < 0.01 by
Mann–Whitney U test. c Representative immunohistochemical stain-
ing of TC-PTP in different grades of SCCs. Scale bar: 5 µm.
d Quantification of TC-PTP expression by immunohistochemistry
scoring. **P < 0.01 by Mann–Whitney U test. e Representative
immunohistochemical staining of TC-PTP, p-STAT3, and p-AKT in
normal human skins, papillomas, and SCCs. Scale bar: 20 µm. f, g
Correlation scatter plots for expression of TC-PTP, p-STAT3, and p-
AKT in human skin tumors. The Pearson correlation coefficient was
calculated with a two-tailed P value. f Correlation between TC-PTP
and p-STAT3 expression. r=−0.60, P < 0.0001. g Correlation
between TC-PTP and p-AKT. r=−0.23, P= 0.044.
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6a). Serine phosphorylation of STAT1 is known to be
crucial for maximal transcriptional activation and STAT1
interaction with transcriptional cofactors [30–32]. Studies
have shown that serine phosphorylation of STAT1 pro-
motes apoptosis. It is required for oxysterol-induced apop-
tosis given that it induces p21waf1 expression [33]. It also
has been demonstrated that PKCδ-dependent phosphoryla-
tion of STAT1 at serine residue increases apoptosis [34].
Similar with these findings, our results showed inhibition of
serine phosphorylation of STAT1 in TC-PTP-
overexpressing cells significantly increased cell survival
after either DMBA or TPA treatment (Figs. 4d and 7c). It
was noted that even though the levels of pS-STAT1 were
higher in TC-PTP-overexpressing cells than control cells,
the level of unphosphorylated STAT1 was lower in TC-
PTP-overexpressing cells than control cells in the absence
or presence of TPA treatment (Fig. 6a, c). Studies have
demonstrated that unphosphorylated STAT1 can promote
tumor development by repressing apoptosis [35]. It is pos-
sible that TC-PTP-mediated downregulation of STAT1
expression may contribute to increased apoptosis and
decreased cell growth in keratinocytes.
PI3K signaling is one of the major cell survival and
proliferation signaling pathways that contribute to cancer
development given that it is an upstream kinase of AKT
[36, 37]. Both WT and TC-PTP-overexpressing keratino-
cytes cultured in serum-free medium constitutively expres-
sed pY-PI3K but its expression was inhibited in both
genotypes after DMBA treatment (Fig. 3b). However, AKT
was still activated in response to DMBA, suggesting that
PI3K-independent activation of AKT contributes to the
inhibition of DMBA-induced apoptosis. In normal kerati-
nocyte medium, pY-PI3K was constitutively expressed in
WT cells only and its expression levels remained the same
until 4 h after TPA treatment. Again, PI3K activation was
completely inhibited in TC-PTP-overexpressing cells (Fig.
6b). We found that TC-PTP did not directly depho-
sphorylate pY-PI3K (Supplementary Fig. S2). While the
interaction of TC-PTP with STAT3 was increased following
TPA treatment, TC-PTP did not interact with PI3K in the
presence or absence of TPA in keratinocytes. Therefore,
further studies remain to be done to elucidate the mechan-
ism by which TC-PTP overexpression prevents PI3K
phosphorylation. In addition, it is possible that TC-PTP can
also regulate DMBA metabolism or DNA damage or repair
after DMBA treatment by dephosphorylating unknown
substrates involved in this mechanism, which can increase
epidermal apoptosis. Further studies are needed to investi-
gate the detailed mechanism by which TC-PTP regulates
DMBA-induced apoptosis.
Chemical carcinogenesis studies using K5HA.Ptpn2 mice
confirmed a tumor suppressive role for TC-PTP in skin
cancer development (Fig. 8c–e). Overexpression of TC-PTP
suppressed skin cancer formation as evidenced by the
overall reduction in tumor incidence and numbers of
tumors. In addition, we found TC-PTP expression was
significantly decreased in human skin papillomas and SCCs
and further decreased with increased grade of SCCs (Fig.
9a–d). Generation of transgenic mice that express a con-
stitutively active form of TC-PTP or utilization of a TC-PTP
activator may be useful methods to further understand the
tumor suppressive role of TC-PTP in skin carcinogenesis. In
summary, our investigation provided evidence that TC-PTP
may be a potential marker for prognosis and modulation of
TC-PTP expression/activation may be a new therapeutic
approach in the prevention and treatment of skin cancer.
Materials and methods
Generation of epidermal-specific
TC-PTP-overexpressing (K5HA.Ptpn2) mice
Transgenic mice that overexpress Ptpn2 in the epidermis
were generated by microinjection of a bovine K5 targeting
vector containing HA-tagged Ptpn2 into the pronuclei of
donor embryos to produce transgenic founders on FVB/N
genetic background. Briefly, HA-tagged full-length mouse
Ptpn2 cDNA from pCMV6/AN/HA [23] was amplified by
PCR and cloned into the NheI and SnaBI sites of the K5
targeting vector. The resulting transgene vector was diges-
ted with KpnI, purified using Qiagen DNA gel extraction kit
and injected into the pronuclei. Transgenic mice were
identified by PCR of genomic DNA isolated from tail snips
using oligonucleotides specific for the gene encoding rabbit
β-globin intron; 5′-TTC AGG GTG TTG TTT AGA ATG
G-3′ and 5′-CAA TAA GAA TAT TTC CAC GCC A-3′.
All experiments were performed by using 6–8 weeks old
female mice, unless otherwise indicated. The dorsal skin of
each mouse was shaved 48 h before treatment; only those
mice in the resting phase of hair cycle were used. All
experiments with mice were carried out with strict adher-
ence to both institutional and National Institutes of Health
guidelines for minimizing distress in experimental animals,
and animal usage was approved by the University of Texas
Rio Grande Valley, Institutional Animal Care and Use
Committee.
Primary keratinocyte cell culture
Two-day-old nontransgenic or K5HA.Ptpn2 neonates were
used to culture primary keratinocytes as described pre-
viously [38]. Briefly, neonates were euthanized and skin
was surgically removed. The skin was then placed in trypsin
for 12 h at 4 °C to remove the dermis. Then, the isolated
epidermis was minced and filtered through a cell strainer
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(70 μm) to remove debris. Primary keratinocytes were pla-
ted and cultured at 37 °C and 5% CO2 in low Ca
2+
(0.03 mM) KGM-2 medium (Lonza, #CC-3158) containing
1% penicillin/streptomycin and 1% fetal bovine serum until
60–70% confluency at which time cells were treated with
DMBA or TPA.
Flow cytometric analysis
Apoptosis of primary keratinocytes was evaluated using
Annexin V-FITC apoptosis kit (Molecular probe, V13242)
according of the manufacturer’s instructions. Briefly, cells
were harvested with 0.25% trypsin; 1 × 106 cells were then
washed with cold PBS and centrifuged at 350 × g for 10 min
and stained using Annexin V-FITC. Then, cell suspensions
were analyzed using LSRFortessa (BD Biosciences). The
apoptotic rate was calculated as of Annexin V-positive
cells. Each experiment was performed three times, and data
were presented as the means ± SD. The cell cycle was
analyzed using FXCycleTM Violet Ready FlowTM Reagent
(Invitrogen, R37166) according to the manufacturer’s
instructions. Briefly, primary keratinocytes obtained from
WT and K5HA.Ptpn2 neonates were incubated in serum-
free medium the day before treatment with TPA or TPA and
STAT1 inhibitor Fludarabine (10 μM). Twelve hours after
treatment, cells were harvested with 0.25% trypsin; 1 × 106
cells were then washed with cold PBS and centrifuged at
350 × g for 5 min and stained using FXCycle. Then, cell
suspensions were analyzed using LSRFortessa. Each
experiment was performed three times, and data were pre-
sented as the means ± SD.
Two-stage carcinogenesis
Female WT and K5HA.Ptpn2 littermates at 7–8 weeks of
age (n= 13/group) were initiated with 25 nmol of DMBA.
Two weeks after DMBA treatment, mice received topical
treatments of 6.8 nmol TPA twice a week until the experi-
ment was terminated. Tumor incidence (percentage of mice
with papillomas) and tumor multiplicity (average number of
papillomas per mouse) were determined weekly until mul-
tiplicity plateaued. Differences in tumor incidence and
multiplicity were analyzed by the likelihood-ratio test and
the Mann–Whitney U test, respectively.
Immunohistochemical analysis
The dorsal skin of mouse was fixed in 10% neutral-buffered
formalin after sacrifice. Human skin cancer and normal
tissues were purchased from Reveal Biosciences (#SK04),
BioChain® (#T2235218-7&8), and SUPER BIO CHIPS
(#CX2). Formalin-fixed and paraffin-embedded tissues were
deparaffinized and hydrated using standard procedures.
Endogenous peroxidase activity was blocked with 0.03%
hydrogen peroxide for 10 min. For the antigen retrieval,
sections were microwaved for 5 min in 10 mM sodium
citrate buffer (pH 6.0) containing 0.01% Tween 20 and
allowed to cool for 20 min. Sections were then stained with
anti-TC-PTP (Proteintech, #11214-1-AP), anti-p-STAT3
(Tyr705) (#9145), and anti-p-AKT (Thr308) (#13038)
(Cell Signaling Technology) antibodies following suggested
procedures by the manufacturer. All specimens were
assessed by hematoxylin & eosin staining for morphology.
Immunoreactivity was determined by scoring according to
the staining intensity (0, none; 1, weak; 2, moderate; 3,
strong) of immunolabeling and percent positive cells (0,
<5%; 1, 6–25%; 2, 26–50%; 3, 51–75%; 4, 76–100%). The
final immunoreactive score was calculated by multiplying
positive cells proportion score by staining intensity score. In
the above analysis, there was no discrepancy between the
two observers regarding the patterns of biomarker expres-
sion and the scores assigned to analyzed sections. Data were
quantified and analyzed with Image J software.
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